Aura reports Phase 2 interim data: 89% tumor control, significant growth rate reduction for choroidal melanoma

Aura Biosciences, Inc.

Interim Phase 2 data for belzupacap sarotalocan (AU-011) in early-stage choroidal melanoma show 88.9% (8/9) tumor control rate at therapeutic regimen.
Statistically significant reduction in tumor growth rate of -0.296 mm/year (p=0.0007) vs. documented historical growth.
Visual acuity preservation rate of 88.9% (8/9) in highest dose cohorts; most tumors were near fovea or optic disc.
No dose-limiting toxicities or treatment-related serious adverse events reported; mild anterior inflammation in 20%.
Data support planned pivotal program; company held virtual investor day on October 3, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.